Dongcheng Biochem(SZ:002675) Shang Hai Zheng Quan Bao·2025-09-25 20:42Core Points - The company has signed a supplementary agreement to the shareholder agreement regarding its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd, in relation to its C-round financing [2][5][9] Group 1: C-Round Financing and Agreements - On February 14, 2025, the company approved a proposal for C-round financing for its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd [2] - Various stakeholders, including the founding shareholders and investment funds, signed the C-round investment agreement and shareholder agreement on February 25, 2025 [2] - The company agreed to repurchase all shares held by Shenzhen Jinglin Jingying Equity Investment Fund Partnership (Limited Partnership) on April 29, 2025, which corresponds to a registered capital of 1.466086 million [3] Group 2: Subsequent Investments and Agreements - On July 18, 2025, the company approved additional investments from several parties, including Yantai Blue Pharmaceutical Valley Construction Development Co., Ltd, to join the C-round investment agreement [4] - The company plans to spin off its subsidiary Lanacheng for a listing on the Hong Kong Stock Exchange, with board meetings held on August 28 and September 15, 2025, to approve related proposals [5] Group 3: Supplementary Agreement Details - The supplementary agreement states that certain rights and obligations under the C-round shareholder agreement will terminate upon the successful IPO of the target company [6] - If specific conditions regarding the IPO application are not met, the original terms of the C-round shareholder agreement will be reinstated [7] - The agreement clarifies that all parties have fulfilled their obligations under the C-round agreements and that there are no ongoing disputes or alternative arrangements [8]